Translating Prognostic and Predictive Biomarkers into Clinic

Posted by

SELECTBIO

Mao Mao, Research Fellow, Pfizer

Abstract
The advances of genomics technologies have allowed us to characterize cancer at molecular level and to generate biomarkers that can predict how individual cancer patients will progress and respond to certain treatments. In this presentation, I will discuss the ongoing efforts for biomarker discovery, validation and translation, the challenges we are facing, and several successes that have guided clinical practice including MammaPrint testing for breast cancer prognosis and treatment decisions and ALK fusion screening as companion diagnostics for Crizotinib treatment.